325 related articles for article (PubMed ID: 30506985)
1. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
Guo CG; Chen L; Chan EW; Cheung KS; Isshiki T; Wong ICK; Leung WK
Aliment Pharmacol Ther; 2019 Jan; 49(1):7-19. PubMed ID: 30506985
[TBL] [Abstract][Full Text] [Related]
2. The risk of dyspnea in patients treated with third-generation P2Y
Zhang N; Xu W; Li O; Zhang B
BMC Cardiovasc Disord; 2020 Mar; 20(1):140. PubMed ID: 32183711
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
4. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
5. Trends for and Clinical Factors Associated with Choice of Oral P2Y
Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Kumar A; Lutsey PL; St Peter WL; Schommer JC; Van't Hof JR; Rajpurohit A; Farley JF
Clin Pharmacol Ther; 2023 Feb; 113(2):412-422. PubMed ID: 36448257
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Potent Oral P2Y
Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
Yoon HY; Lee N; Seong JM; Gwak HS
Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492
[TBL] [Abstract][Full Text] [Related]
9. Impact of Ticagrelor Versus Clopidogrel on Bleeding Outcomes of Isolated Coronary Artery Bypass Grafting.
Ingrassia JJ; Mosleh W; Conner CM; Mather JF; Loya DS; Yaffee DW; Sutton TS; Takata ET; McMahon SR; Hashim SW; McKay RG
Cardiovasc Revasc Med; 2023 Jan; 46():44-51. PubMed ID: 35961855
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis Comparing Potent Oral P2Y
Casula M; Fortuni F; Ferlini M; Fabris F; Oltrona Visconti L; Leonardi S
Am J Cardiovasc Drugs; 2021 Mar; 21(2):231-240. PubMed ID: 32895853
[TBL] [Abstract][Full Text] [Related]
11. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
12. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K
Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690
[TBL] [Abstract][Full Text] [Related]
13. Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Kang J; Han JK; Ahn Y; Chae SC; Kim YJ; Chae IH; Hur SH; Seong IW; Chae JK; Cho MC; Seung KB; Jeong MH; Yang HM; Park KW; Kang HJ; Koo BK; Kim HS;
Thromb Haemost; 2018 Mar; 118(3):591-600. PubMed ID: 29534250
[TBL] [Abstract][Full Text] [Related]
14. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.
Hong J; Turgeon RD; Pearson GJ
Ann Pharmacother; 2019 Oct; 53(10):997-1004. PubMed ID: 30999764
[No Abstract] [Full Text] [Related]
15. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Schilling U; Dingemanse J; Dobrow M; Baumann M; Riederer MA; Juif PE; Ufer M
Thromb Haemost; 2021 Jun; 121(6):755-766. PubMed ID: 33412611
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.
Serenelli M; Pavasini R; Vitali F; Tonet E; Bilotta F; Parodi G; Campo G
J Thromb Haemost; 2019 Jun; 17(6):944-950. PubMed ID: 30884109
[TBL] [Abstract][Full Text] [Related]
17. Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.
Brown O; Rossington J; Buchanan GL; Patti G; Hoye A
Curr Vasc Pharmacol; 2019; 17(2):191-203. PubMed ID: 29359672
[TBL] [Abstract][Full Text] [Related]
18. How Do Type of Preoperative P2Y
Voetsch A; Pregartner G; Berghold A; Seitelberger R; Schoerghuber M; Toller W; Mahla E
Ann Thorac Surg; 2021 Jan; 111(1):77-84. PubMed ID: 32565086
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
20. Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting.
Holm M; Biancari F; Khodabandeh S; Gherli R; Airaksinen J; Mariscalco G; Gatti G; Reichart D; Onorati F; De Feo M; Santarpino G; Rubino AS; Maselli D; Santini F; Nicolini F; Zanobini M; Kinnunen EM; Ruggieri VG; Perrotti A; Rosato S; Dalén M
Ann Thorac Surg; 2019 Jun; 107(6):1690-1698. PubMed ID: 30898561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
